LOGIN  |  REGISTER
Amneal Pharmaceuticals

Cassava Sciences Mourns the Death of Board Member Sanford “Sandy” Robertson

August 05, 2024 | Last Trade: US$3.70 0.11 -2.83

AUSTIN, Texas, Aug. 05, 2024 (GLOBE NEWSWIRE) -- Cassava Sciences, Inc. (Nasdaq: SAVA) today reflected on the passing of long-time board member Sanford Robertson.

We are profoundly saddened by the passing of our dear friend and colleague, Sandy Robertson. Sandy served on the Board of Directors of Cassava Sciences since its inception as a public company in 1998. Sandy's commitment to Cassava’s mission and success was unwavering. Sandy’s success in the business world is well recognized by the hundreds of companies that he helped build and the entrepreneurs who created those companies. Everyone who knew or worked alongside Sandy understood his powerful intelligence as well as his remarkable kindness. His success in business was legendary but what those who knew him will remember was who he was: Sandy was the personification of someone who would treat others as he would like to be treated. We will miss him terribly as will anyone who knew him.

About Cassava Sciences, Inc.

Cassava Sciences is a clinical-stage biotechnology company based in Austin, Texas. Our mission is to detect and treat neurodegenerative diseases, such as Alzheimer’s disease. For more information, please visit: https://www.CassavaSciences.com  

For More Information Contact:
Eric Schoen, Chief Financial Officer
(512) 501-2450, or This email address is being protected from spambots. You need JavaScript enabled to view it.

Assertio

Stock Quote

Featured Stock

Cue Biopharma

Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...

CLICK TO LEARN MORE

Featured Stock

Astria Therapeutics

Astria Therapeutics is a biopharmaceutical company, and our mission is to bring life-changing therapies to patients and families affected by rare and niche allergic and immunological diseases. Our lead program, STAR-0215, is a monoclonal antibody inhibitor of plasma kallikrein in clinical development...

CLICK TO LEARN MORE

End of content

No more pages to load

Next page